Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Short-term Investments (2020 - 2026)

InMed Pharmaceuticals has reported Short-term Investments over the past 5 years, most recently at $42675.0 for Q4 2025.

  • For Q4 2025, Short-term Investments rose 4.63% year-over-year to $42675.0; the TTM value through Dec 2025 reached $42675.0, up 4.63%, while the annual FY2025 figure was $43384.0, 0.74% up from the prior year.
  • Short-term Investments for Q4 2025 was $42675.0 at InMed Pharmaceuticals, roughly flat from $42859.0 in the prior quarter.
  • Over five years, Short-term Investments peaked at $46391.0 in Q2 2021 and troughed at $40582.0 in Q1 2025.
  • A 5-year average of $43551.5 and a median of $43085.0 in 2024 define the central range for Short-term Investments.
  • Biggest five-year swings in Short-term Investments: fell 8.27% in 2024 and later increased 4.63% in 2025.
  • Year by year, Short-term Investments stood at $45356.0 in 2021, then decreased by 5.08% to $43053.0 in 2022, then rose by 3.27% to $44462.0 in 2023, then fell by 8.27% to $40787.0 in 2024, then increased by 4.63% to $42675.0 in 2025.
  • Business Quant data shows Short-term Investments for INM at $42675.0 in Q4 2025, $42859.0 in Q3 2025, and $43384.0 in Q2 2025.